Low versus high I-131 dose for remnant ablation in differentiated thyroid cancer

Clinical Medicine and Research

Volumn 7, Issue 1-2, 2009, Pages 1-

  Hackshaw, Allan ^a   Mallick, Ujjal ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131;

CLINICAL TRIAL; DATA ANALYSIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG USE; EVIDENCE BASED MEDICINE; HUMAN; LETTER; LOW DRUG DOSE; METHODOLOGY; RISK FACTOR; THYROID CANCER;

CARCINOMA, PAPILLARY; CELL DIFFERENTIATION; DATA INTERPRETATION, STATISTICAL; HUMANS; IODINE RADIOISOTOPES; NEOPLASM RECURRENCE, LOCAL; RADIATION DOSAGE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RISK; RISK FACTORS; THYROID NEOPLASMS;

EID: 68249138725     PISSN: 15394182     EISSN: None     Source Type: Journal    
DOI: 10.3121/cmr.2009.841     Document Type: Letter

References (4)

1. Doi SA, Woodhouse NJ, Thalib L, Onitilo A. Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: a meta-analysis revisited. Clin Med Res 2007; 5:87-90.
2. 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrinol Metab 2007;92:28-38.
3. Egger M, Schneider M, Davey Smith G. Spurious precision? Meta-analysis of observational studies. BMJ 1998;316: 140-144.
4. Mallick U, Harmer C, Hackshaw A. The HiLo trial: a multicentre randomised trial of high- versus low-dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation after surgery for differentiated thyroid cancer. Clin Oncol (R Coll Radiol) 2008;20:325-326.